Curaleaf Holdings shares slipped on Monday, November 9, even as the rest of the Toronto market enjoyed one of its best days in weeks. The cannabis operator issued no fresh news of its own on the day. The drop came as investors kept weighing its bidding war with Organigram for Aurora Cannabis, which Curaleaf's chief executive has promised to fight with a richer offer.

What happened

Curaleaf (TSX:CURA) closed at C$12.68, down C$0.55 on the session. It ranked among the worst performers on the S&P/TSX Composite, which rose about 657 points to 36,446.26, its highest close since early September.

The broad market was strongly risk-on. Base metals led, industrials and financials gained, and advancers beat decliners by more than two to one on the exchange. Curaleaf moved the other way.

Why it matters

The backdrop is a Takeover fight that has turned against Curaleaf in the past week.

Curaleaf launched a hostile bid for Aurora Cannabis in August and sweetened it on October 6 to 0.4013 Curaleaf shares plus US$1 in cash for each Aurora share. Aurora's board rejected both versions.

On Tuesday, November 3, Organigram signed a friendly deal to buy Aurora for C$7.80 a share, or about C$561 million, in cash and stock. That price sits well above the implied value of Curaleaf's offer, and both boards back it unanimously.

Curaleaf said its own bid remains open and that it "believes its offer represents better value." On its third-quarter call the next day, chairman and chief executive Boris Jordan went further: "The one thing I can say, though, is that Curaleaf is going to improve our bid substantially."

He did not name a price. He also said Curaleaf would not raise its offer materially without access to Aurora's books.

For Curaleaf shareholders, that matters. Because the bid is paid mostly in Curaleaf stock, a bigger offer would likely mean issuing more shares. Investors have to judge whether Aurora is worth that dilution.

The bigger picture

Curaleaf's own Business is holding up. Third-quarter Revenue rose to US$352.7 million from US$317.9 million a year earlier. International sales grew faster than the US side, and Florida now has 78 of its stores.

But the company still lost US$32.7 million in the quarter, and adjusted gross Margin narrowed. Jordan said Demand stayed resilient "against a backdrop of increasing pressure on the consumer."

Curaleaf has been part of the S&P/TSX Composite since September 2025, when it became the first US cannabis operator added to Canada's benchmark. That inclusion brings it more index money, but it also means bigger swings when sentiment shifts.

Cannabis stocks also tend to move sharply on any word about US federal rescheduling.

What to watch next

The key date is December 4, when Curaleaf's offer for Aurora is set to expire. Before then, investors will want to see whether Curaleaf follows through on a higher bid, what it is willing to pay, and how much new stock it would issue.

Watch too for details of the Organigram agreement, such as any break fee, which Curaleaf has said it is waiting to see. The Organigram deal is expected to close in January 2027, subject to shareholder, court and regulatory approvals.

For now, Monday's slide suggests the market is cautious about how costly winning Aurora could become.